Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2021-08-19 M&A Activity
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
[기재정정]지주회사의자회사편입
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korean DART system regarding a 'Holding Company's Subsidiary Incorporation' (지주회사의 자회사 편입). It details the acquisition of a subsidiary (Daewoong Pet), including financial data, ownership percentages, and the date of incorporation. Since this is a specific corporate event announcement regarding business structure and subsidiary acquisition that does not fit into the other specialized categories like M&A (which usually refers to full company takeovers) or Share Issues, it is best classified as a general Regulatory Filing (RNS).
2021-08-19 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Daewoong' covering the period from January 1, 2021, to June 30, 2021. It contains detailed financial information, business descriptions, management discussions, and corporate governance details, which are characteristic of an interim financial report. It is not an announcement of a report (RPA) as it contains the full content of the report itself. H1 2021
2021-08-17 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Report' (잠정실적) for Daewoong, detailing quarterly financial highlights such as revenue, operating profit, and net income. It is a short, structured announcement of financial results rather than a full annual or interim report. According to the filing definitions, this fits the 'Earnings Release' (ER) category, as it provides key financial highlights for the period. Q2 2021
2021-07-29 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)(펙수프라잔(Fexuprazan) 기술이전(Licensing Out) 계약 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from Daewoong Pharmaceutical regarding a 'Licensing Out' agreement for their drug 'Fexuprazan' with Neurogastrx, Inc. This is a material corporate event announcement detailing a business transaction (licensing/partnership). While it involves a contract, it does not fit the specific M&A (merger/takeover) category, nor is it a financial report or dividend notice. It is a standard regulatory disclosure of a significant business development, which falls under the 'Regulatory Filings' (RNS) category as a catch-all for material corporate announcements in this taxonomy.
2021-06-08 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company Daewoong, covering the period from January 1, 2021, to March 31, 2021. It contains detailed corporate information, financial data, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-17 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Daewoong, detailing key financial metrics like revenue, operating profit, and net income for the first quarter of 2021. It provides a summary of financial performance rather than a full comprehensive report, and it is explicitly labeled as provisional (잠정치). This fits the definition of an Earnings Release (ER). Q1 2021
2021-05-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.